The Endpoints poll: A large majority of biopharma execs turn thumbs down on Biogen's controversial pitch for aducanumab
There’s a big vote looming at the end of the week as outside experts at the FDA put Biogen’s Alzheimer’s drug aducanumab on trial. But …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
